ALK-Abello product Grazax approved in 27 countries

ALK-Abello has announced that its disease-modifying allergy treatment Grazax has been authorised for use in 27 EU countries following the first set of results of a long-term study.

Grazax – which is the only registered tablet therapy against grass pollen – was found by the trial to significantly improve symptoms of the eyes and nose when the recommended treatment was followed to completion.

Those participating in the trial adhered to the therapy for a total of three years, completing the course of their medication in autumn 2007 in time for the effects to be monitored in the summer of 2008.

ALK-Abello is now the first company to have reported a sustained disease-modifying effect of an allergy immunotherapy tablet.

Last month, Alk-Abello released its financial report for the six-months ending June 30th 2009 and revealed that its revenue for the period stood at 927 million Danish krone (106.5 million pounds).